In summary, a combined TKI/early LT strategy in EGFR+ and ALK+ NSCLC with BM improves icPFS but not OS, regardless of the radiotherapy technique (SRT or WBRT) and number of brain lesions. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.